All articles Biotech Funding 6 min read

Stop valuing a biotech on its platform slide

Platform stories raise first rounds. Partners and later investors pay for assets and data. Young biotech companies would do better to lead with the second and let the platform earn its place.

A presentation slide of a sprawling platform diagram beside a single tall bar for one drug candidate moving through trial phases
Tomás Ferreira

Devices and biotech writer

Every young biotech has the slide. A circle in the middle labelled with the technology, a dozen arrows pointing out to disease areas, and the word platform somewhere in large type. It is a good slide for a first round. It is a poor way to run a company.

Buyers pay for assets

When a larger company licenses, partners or acquires, it is usually paying for something specific: a candidate with data in a disease it cares about, or a capability it can put a price on. The platform matters because it produced that candidate and might produce the next one. On its own it is a promise, and promises are discounted heavily in a term sheet. Large studies of clinical trial success rates show that most candidates entering clinical testing never reach approval, and buyers price that in.

Founders know this, which is why the platform slide so often survives into later decks while the lead program sits on page eleven. That order is backwards.

We spent two years explaining the platform. The deal happened in six weeks once we had one clean data readout.

Chief business officer, preclinical-stage drug developer

Focus is not a lack of ambition

Spreading a small team across five indications to prove breadth usually means none of them reaches a decisive experiment. Choosing one program, funding it to a readout that would change a partner's mind, and saying so plainly, is not small thinking. It is the fastest route to the money that pays for the other four.

What I would put on slide two

The lead candidate, the disease, the patients, and the one result that would make it worth licensing, with a date and a budget to reach it. For a drug candidate, that plan runs through the investigational new drug requirements before any human data exist, which is one more reason to cost it honestly. Then the platform, as the reason there will be a second candidate. Investors who only want the platform story will still find it. The ones who write the larger cheques later will notice you led with the part they pay for.

Buyers further down the line think the same way. A hospital value analysis committee asks what a product changes before it asks how clever it is, and practices want to know whether a new therapy will clear prior authorization and get paid without a pile of claim denials. A company that answers those questions early is easier to partner with.

TL;DR If you only remember this

  1. Partners and acquirers mostly pay for specific assets and data, not platforms.
  2. A platform is valued for what it has produced and might produce next.
  3. Funding one program to a decisive readout often beats spreading across many.
  4. Lead with the asset and its next milestone; let the platform explain the pipeline.

About the writer

Tomás Ferreira

Devices and biotech writer

Tomás Ferreira covers medical devices and biotech. A former hospital supply chain analyst who later worked on partnering at a small drug developer, Tomás writes about how products get evaluated, bought and funded, from value analysis committees to licensing term sheets.

  • medical devices
  • hospital procurement
  • biotech funding
  • licensing
More from Tomás →

The Friday round

Free · every Friday

Hi, I'm , I work as , and I'd like five stories about

every Friday.

2 topics picked · No ads, no spam, unsubscribe any time.